- You are here:
- Home »
- Blog »
- prostate cancer »
- Chemotherapy-induced Cardiomyopathy in Prostate Cancer
Chemotherapy-induced Cardiomyopathy in Prostate Cancer
Chemotherapy-induced Cardiomyopathy in Prostate Cancer is a concern now and in the future. That is to say that conventional prostate cancer therapies, according to the research linked below, can cause heart damage to the PCa patient immediately or years after treatment.
The purpose of this post is to highlight the problem for PCa patients and survivors and then outline possible therapies. I am a long-term survivor of a different cancer. I was diagnosed with chemotherapy-induced cardiomyopathy 15 years AFTER my treatment.
My goal is to highlight non-conventional heart health therapies.
Heart-healthy diet and prostate cancer
Researching PCa and heart health indicates that these two diseases are intertwined. Yes, PCa therapies such as ADP can cause heart damage but many PCa patients have pre-existing heart damage which complicates this relationship.
My approach as a cancer survivor living with chemotherapy-induced cardiovascular disease is to live a heart-healthy lifestyle through diet (see the video above), exercise, and supplementation- see the list below of those supplements that I take.
Consider:
- CoQ10
- DHEA
- Omega-3 fatty acids
- Curcumin
- Vitamin D3
- Cocoa
- Carnitine
- D-Ribose
several other supplements.
Have you been diagnosed with both prostate cancer and heart damage? Scroll down the page, post a question or comment, and I will reply to you ASAP.
Hang in there,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
Cardiovascular Risk in Prostate Cancer
Abstract
Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to thresholds recommended by cardiovascular practice guidelines.
Androgen deprivation therapy reduces muscle strength and increases adiposity, increasing the risk for diabetes and hypertension, although its relationship with adverse cardiovascular events requires confirmation. Androgen receptor pathway inhibitors, including androgen receptor antagonists and cytochrome P450 17A1 inhibitors, confer incremental risks for hypertension and cardiovascular events to androgen deprivation therapy. Lower cardiovascular risk with gonadotropin-releasing hormone antagonists compared with agonists requires confirmation in well-designed randomized trials.
Risk of Cardiovascular Disease in Cancer Survivors after Systemic Treatment
Background
Patients face an increased risk of cardiovascular disease shortly after a cancer diagnosis, but evidence on long-term risk among cancer survivors remains limited.
Objectives
In this study the authors sought to estimate the risk of cardiovascular disease in cancer survivors previously treated with systemic cancer therapy.
Methods
Using Danish population-based registries, we identified individuals who had received systemic cancer treatment and were free of both cancer and treatment 3 years after diagnosis (index date). For each cancer survivor, 5 cancer-free individuals from the general population were randomly selected, matched by birth year, sex, and calendar year. Participants were followed from the index date for up to 5 years. HRs were estimated using Cox regression, adjusted for potential confounders.
Results
Compared with 457,035 matched individuals, the 91,407 cancer survivors had an increased risk of
- heart failure or cardiomyopathy (HR: 1.08; 95% CI: 1.02-1.15),
- venous thromboembolism (HR: 1.50; 95% CI: 1.41-1.61),
- pericarditis, endocarditis, or myocarditis (HR: 1.30; 95% CI: 1.11-1.52),
- and kidney failure (HR: 1.17; 95% CI: 1.10-1.25),
but not of ischemic heart disease, stroke, or atrial fibrillation. Estimates varied substantially by cancer type and treatment agent. For example, venous thromboembolism risk was consistently increased across nearly all cancer types, whereas hypertension risk was elevated for none. Ischemic heart disease risk was increased only among lung cancer survivors. Stroke was associated with platinum compounds but not with other systemic treatments.
Conclusions
Several cardiovascular disease risks were elevated among cancer survivors, with substantial variation by cancer type and treatment.
Chemotherapy-induced Cardiomyopathy in Prostate Cancer Chemotherapy-induced Cardiomyopathy in Prostate Cancer